%0 Case Reports
%T A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review.
%A Liu Y
%A Li M
%A Guo Y
%A Zhang Z
%A Du L
%A Zhang X
%A Wang Y
%A Zhang D
%A Xue L
%A Lei B
%A Su J
%A Zhang R
%A Chen J
%A Zhang X
%A Jia Q
%A Tian C
%J Pathol Res Pract
%V 259
%N 0
%D 2024 Jul 28
%M 38820929
%F 3.309
%R 10.1016/j.prp.2024.155371
%X <B>BACKGROUND: </B>Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with BRAF V600E mutation-positive NSCLC. Nevertheless, the treatment strategy for NSCLC patients with BRAF non-V600E mutations remains limited.<BR><B>METHODS: </B>Here, we present a NSCLC patient with a BRAF N581S mutation, which is a class III BRAF mutation, and this patient had a durable response to targeted therapy with combined anlotinib and tislelizumab.<BR><B>CONCLUSIONS: </B>We hope to bring more attention to rare non-V600 BRAF mutations by presenting this case of NSCLC.